Literature DB >> 22198481

Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2.

Yun Hee Kang1, Mi-Young Park, Do-Young Yoon, Seung Ro Han, Chung Il Lee, Na Young Ji, Pyung-Keun Myung, Hee Gu Lee, Jae Wha Kim, Young Il Yeom, Ye Jin Jang, Dong Kuk Ahn, Jong Wan Kim, Eun Young Song.   

Abstract

IL-32 is a newly discovered cytokine. Recently, various reports suggest that it plays a role as a proinflammatory mediator and may be involved in several cancer carcinogenesis. However, IL-32 expression in hepatocellular carcinoma (HCC) remains unclear. In this study, we investigated the expression and role of IL-32α in hepatocellular carcinoma, because IL-32 was identified as an upregulated gene in hepatocellular carcinoma tissues compared to nontumorous regions using DNA microarray. IL-32α was overexpressed in tissue and serum from patients with HCC and localized in the cytoplasm and nucleus of hepatocellular carcinoma tumor cells. Moreover, secreted IL-32α concentration in the serum of patients with hepatocellular carcinoma was elevated as compared with those in the normal serum using a developed sandwich ELISA. Furthermore, IL-32α suppression in hepatocellular carcinoma decreased expression of phospho-p38 MAPK, NF-κB, and antiapoptotic protein Bcl-2 and induced expression of proapoptotic proteins as well as p53 and PUMA resulting in the suppression of cell growth and induction of intrinsic apoptosis. Based on our results, we suggest that IL-32α is involved in the progression of hepatocellular carcinoma and may be a useful biomarker for diagnosis and therapeutic target of hepatocellular carcinoma. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198481     DOI: 10.1016/j.canlet.2011.12.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Authors:  Xiuzhang Yu; Bin Zhou; Zhu Zhang; Qianqian Gao; Yanyun Wang; Yaping Song; Yan Pu; Yue Chen; Ruiqi Duan; Lin Zhang; Mingrong Xi
Journal:  Tumour Biol       Date:  2015-02-09

2.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

4.  IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

Authors:  Hanako Ohmatsu; Daniel Humme; Juana Gonzalez; Nicholas Gulati; Markus Möbs; Wolfram Sterry; James G Krueger
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

5.  Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer.

Authors:  Jieun Kang; Yun Hee Kang; Byung Moo Oh; Tae Gi Uhm; Sang Yoon Park; Tae Woo Kim; Seung Ro Han; Seon-Jin Lee; Younghee Lee; Hee Gu Lee
Journal:  Tumour Biol       Date:  2016-08-02

Review 6.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

7.  Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer.

Authors:  Kayhan Erturk; Didem Tastekin; Murat Serilmez; Elif Bilgin; Hamza Ugur Bozbey; Sezai Vatansever
Journal:  Tumour Biol       Date:  2015-07-29

8.  Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues.

Authors:  Audrey Player; Tim Oguamanam; Jennifer Okanmelu; Kayla Burrell; Mario Hollomon
Journal:  BMC Res Notes       Date:  2014-08-07

Review 9.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

Review 10.  Role of interleukin-32 in cancer biology.

Authors:  Haimeng Yan; Donghua He; Xi Huang; Enfan Zhang; Qingxiao Chen; Ruyi Xu; Xinling Liu; Fuming Zi; Zhen Cai
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.